Search

Your search keyword '"Cordua, Nadia"' showing total 17 results
Start Over Author "Cordua, Nadia"
17 results on '"Cordua, Nadia"'

1. Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney

Author

Giudice, Giulia Claire, Maruzzo, Marco, Verzoni, Elena, Procopio, Giuseppe, Bimbatti, Davide, Sepe, Pierangela, Maines, Francesca, Grillone, Francesco, Cavo, Alessia, Santoni, Matteo, Cordua, Nadia, Pecoraro, Giovanna, Prati, Veronica, Napoli, Marilena Di, Ollari, Eli, Caruso, Giuseppe, Simoni, Nicola, Campobasso, Davide, and Buti, Sebastiano

Published
2024
Full Text
View/download PDF

2. STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines

Author

Proto, Claudia, Manglaviti, Sara, Lo Russo, Giuseppe, Musca, Marco, Galli, Giulia, Imbimbo, Martina, Perrino, Matteo, Cordua, Nadia, Rulli, Eliana, Ballatore, Zelmira, Dal Maso, Alessandro, Chella, Antonio, Sbrana, Andrea, Prelaj, Arsela, Ferrara, Roberto, Occhipinti, Mario, Brambilla, Marta, De Toma, Alessandro, Mazzeo, Laura, Beninato, Teresa, Signorelli, Diego, Massa, Giacomo, Greco, Francesca Gabriella, Calareso, Giuseppina, Miliziano, Daniela, Di Mauro, Rosa Maria, Mella, Giulia, Lucarelli, Alessandra, Paggio, Angela, Galli, Francesca, Torri, Valter, de Braud, Filippo Guglielmo Maria, Pasello, Giulia, Petrini, Iacopo, Berardi, Rossana, Ganzinelli, Monica, Garassino, Marina Chiara, and Zucali, Paolo Andrea

Published
2023
Full Text
View/download PDF

3. New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy

Author

CECI, Francesco, primary, AIRÒ FARULLA, Lighea S., additional, BONATTO, Elena, additional, EVANGELISTA, Laura, additional, ALIPRANDI, Marta, additional, CECCHI, Luigi G., additional, MATTANA, Francesco, additional, BERTOCCHI, Alessandro, additional, DE VINCENZO, Fabio, additional, PERRINO, Matteo, additional, CORDUA, Nadia, additional, BOREA, Federica, additional, and ZUCALI, Paolo A., additional

Published
2024
Full Text
View/download PDF

4. Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

Author

Conforti, Fabio, Zucali, Paolo Andrea, Pala, Laura, Catania, Chiara, Bagnardi, Vincenzo, Sala, Isabella, Della Vigna, Paolo, Perrino, Matteo, Zagami, Paola, Corti, Chiara, Stucchi, Sara, Barberis, Massimo, Guerini-Rocco, Elena, Di Venosa, Benedetta, De Vincenzo, Fabio, Cordua, Nadia, Santoro, Armando, Giaccone, Giuseppe, and De Pas, Tommaso Martino

Published
2022
Full Text
View/download PDF

5. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs

Author

Perrino, Matteo, primary, Voulaz, Emanuele, additional, Balin, Simone, additional, Cazzato, Gerardo, additional, Fontana, Elena, additional, Franzese, Sara, additional, Defendi, Martina, additional, De Vincenzo, Fabio, additional, Cordua, Nadia, additional, Tamma, Roberto, additional, Borea, Federica, additional, Aliprandi, Marta, additional, Airoldi, Marco, additional, Cecchi, Luigi Giovanni, additional, Fazio, Roberta, additional, Alloisio, Marco, additional, Marulli, Giuseppe, additional, Santoro, Armando, additional, Di Tommaso, Luca, additional, Ingravallo, Giuseppe, additional, Russo, Laura, additional, Da Rin, Giorgio, additional, Villa, Anna, additional, Della Bella, Silvia, additional, Zucali, Paolo Andrea, additional, and Mavilio, Domenico, additional

Published
2024
Full Text
View/download PDF

6. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy

Author

Perrino, Matteo, primary, Cordua, Nadia, additional, De Vincenzo, Fabio, additional, Borea, Federica, additional, Aliprandi, Marta, additional, Cecchi, Luigi Giovanni, additional, Fazio, Roberta, additional, Airoldi, Marco, additional, Santoro, Armando, additional, and Zucali, Paolo Andrea, additional

Published
2023
Full Text
View/download PDF

7. Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?

Author

Borea, Federica, primary, Franczak, Marika A., additional, Garcia, Maria, additional, Perrino, Matteo, additional, Cordua, Nadia, additional, Smolenski, Ryszard T., additional, Peters, Godefridus J., additional, Dziadziuszko, Rafal, additional, Santoro, Armando, additional, Zucali, Paolo A., additional, and Giovannetti, Elisa, additional

Published
2023
Full Text
View/download PDF

9. Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma

Author

Tufano, Antonio, primary, Cordua, Nadia, additional, Nardone, Valerio, additional, Ranavolo, Raffaele, additional, Flammia, Rocco Simone, additional, D’Antonio, Federica, additional, Borea, Federica, additional, Anceschi, Umberto, additional, Leonardo, Costantino, additional, Morrione, Andrea, additional, and Giordano, Antonio, additional

Published
2022
Full Text
View/download PDF

11. Advances in drug treatments for mesothelioma

Author

Zucali, Paolo Andrea, primary, De Vincenzo, Fabio, additional, Perrino, Matteo, additional, Digiacomo, Nunzio, additional, Cordua, Nadia, additional, D’Antonio, Federica, additional, Borea, Federica, additional, Fazio, Roberta, additional, Pirozzi, Angelo, additional, and Santoro, Armando, additional

Published
2022
Full Text
View/download PDF

12. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy

Author

Perrino, Matteo, primary, De Pas, Tommaso, additional, Bozzarelli, Silvia, additional, Giordano, Laura, additional, De Vincenzo, Fabio, additional, Conforti, Fabio, additional, Digiacomo, Nunzio, additional, Cordua, Nadia, additional, D'Antonio, Federica, additional, Borea, Federica, additional, Santoro, Armando, additional, and Zucali, Paolo Andrea, additional

Published
2021
Full Text
View/download PDF

16. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy.

Author

Perrino, Matteo, De Pas, Tommaso, Bozzarelli, Silvia, Giordano, Laura, De Vincenzo, Fabio, Conforti, Fabio, Digiacomo, Nunzio, Cordua, Nadia, D'Antonio, Federica, Borea, Federica, Santoro, Armando, and Zucali, Paolo Andrea

Subjects
THYMOMA, VASCULAR endothelial growth factor receptors, FIBROBLAST growth factor receptors, PLATELET-derived growth factor receptors, FALSE positive error, REGORAFENIB
Abstract

Background: Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet‐derived growth factor receptor β (PDGFR‐β), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2‐B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum‐containing chemotherapy. Methods: A Fleming single‐arm, single‐stage, phase 2 trial to evaluate the activity of regorafenib (160 mg once a day by mouth for 3 weeks on/1 week off) was planned. The study was designed to reject the null hypothesis of an 8‐week progression‐free survival (PFS) rate ≤25% with a type I error of 0.10 and a statistical power of 80% at the alternative hypothesis of an 8‐week PFS rate of ≥50% (≥8 of 19 evaluable patients progression‐free at 2 months). Results: From June 2016 to November 2017, 19 patients were enrolled (11T/8TC). We observed partial response (PR) in 1 patient (1T) (5.3%), stable disease (SD) in 14 patients (9T/5TC) (73.7%), and progressive disease in 2 patients (1T/1TC) (10.5%), with a disease control rate of 78.9%. According to Choi‐criteria, 13 patients (68.4%) achieved PR, and 2 patients SD (10.5%). The median PFS was 9.6 months whereas median overall survival was 33.8 months. The 8‐week PFS rate was 78.9% (15 of 19 patients). Grade 3‐4 treatment‐related adverse events were observed in 10 patients (52.6%). Conclusions: The primary end point of this study was reached. The high rate of PR (Choi‐criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies. The results of the activity and toxicity profile of regorafenib observed in this small series of thymic epithelial tumors are encouraging and should be better evaluated in subsequent larger and specific study phases. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

17. A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.

Author

Perrino, Matteo, primary, Bozzarelli, Silvia, additional, Zucali, Paolo Andrea, additional, De Pas, Tommaso Martino, additional, Simonelli, Matteo, additional, De Vincenzo, Fabio, additional, Conforti, Fabio, additional, Persico, Pasquale, additional, Miggiano, Chiara, additional, Cordua, Nadia, additional, Cioffi, Angela, additional, Sala, Simona, additional, Mrakic Sposta, Federica, additional, Giordano, Laura, additional, and Santoro, Armando, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results